-
Mashup Score: 2Harnessing the Immune System to Its Full Potential: Immunologic Approaches to Multiple Myeloma Management - 1 day(s) ago
An Education Session at the 2025 ASCO Annual Meeting will explore current and future opportunities for immunotherapy—including quadruplet regimens and bispecific T-cell engagers—in newly diagnosed multiple myeloma.
Source: dailynews.ascopubs.orgCategories: General Medicine NewsTweet
-
Mashup Score: 3
An unprecedented wave of oncologist faculty leaving or planning to leave their institutions led ASCO to develop eight recommendations for academic medical centers.
Source: www.oncologynewscentral.comCategories: General Medicine NewsTweet-
Check my comments on @ASCO recent recommendations on Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists @OncNewsCentral @UAMSMyeloma ➡️ https://t.co/JtpzQ2Eghw
-
-
Mashup Score: 3Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment - 24 day(s) ago
Potentially fatal non-ICANS neurotoxicities (NINTs) following BCMA-targeted CAR T-cell therapy have been linked to high CAR T-cell expansion and prolonged
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment #mmsm @BloodJournal ➡️https://t.co/NyFZtGktK2 🛑~ 1 out of 3 pts (n= 13/42) treated with Cilta cel developed non-ICANS neurotoxicities, onset ~ 1 month (range 17-47 days), types of https://t.co/XHZr06t5u8
-
-
Mashup Score: 0Get Involved | ASH News Daily | American Society of Hematology - 1 month(s) ago
Get Involved | ASH News Daily | American Society of Hematology ASH News Daily Seeks New Blood! ASH is in search of the next team of authors for the 2025 ASH News Daily, the official print publication of the ASH annual meeting. If you are an early to mid-career ASH member (MD, PhD, or equivalent) who has a passion for writing as…
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Great opportunity to be part of ASH News Daily @ASH_hematology #ASH25 If you are early to mid-career hematologist who possess a love of writing. Consider this (you can work with a trainee) More details, including how to apply, are here: ➡️ https://t.co/HBoh1SGtIh https://t.co/g7u52VeAq7
-
-
Mashup Score: 16Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial - 3 month(s) ago
Key Points. Induction therapy with IsaKRD in the MIDAS study yielded the highest pre-transplant MRD-negativity rates ever reported in TE NDMM patientsThe f
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
#mmsm @BloodJournal MIDAS study of IsaKRD-results of induction /6 cycles n=791 8% high risk cytogenetics 91% VGPR or better MRD negativity: ~ 2/3 achieved to 10-5 and 1/2 achieved 10-6 ➡️ https://t.co/mrPmR6Ked7 Imp study with post-induction MRD assessment for guiding… https://t.co/TzkuzAdRsG https://t.co/W85YwIcNf9
-
-
Mashup Score: 2Samer Al Hadidi: The longest follow up of any myeloma phase III clinical trial - OncoDaily - 4 month(s) ago
Samer Al Hadidi: The longest follow up of any myeloma phase III clinical trial / Anup Trikannad, Asis Shrestha, cancer, Meera Mohan, multiple myeloma,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: The longest follow up of any myeloma phase III clinical trial - @HadidiSamer @UAMSMyeloma https://t.co/SAMEvVCA1L #Cancer…
-
-
Mashup Score: 4Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants - 4 month(s) ago
Abstract. Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk multiple myeloma were randomized between a standard arm (TT4-S) and a light arm (TT4-L). TT4-L employed one instead of two inductions and consolidations. To compensate for potential loss of efficacy of TT4-L, bortezomib and thalidomide were added to fractionated melphalan 50 mg/m2/d for 4 days.Results: Grade ≥3 toxicities and treatment-related mortalities were not reduced in TT4-L. Complete response (CR) rates were virtually identical (P = 0.2; TT4-S, 59%; TT4-L, 61% at 2 years), although CR duration was superior with TT4-S (P = 0.05; TT4-S, 87%; TT4-L, 81% at 2 years). With a median follow-up of 4.5 years, there was no difference in overall survival (OS) and progression-free survival (PFS). Whereas metaphase cytogenetic abnormalities (CAs) tended to be an a
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
We will be publishing soon data on TT IV focusing only on patients with standard risk myeloma All those approaches didn’t use upfront Dara (anti-CD38) therapy and intended to do tandem auto transplant Earlier results published a while ago: https://t.co/c7AN0kns5l
-
-
Mashup Score: 82Long Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma - 4 month(s) ago
Samer Al Hadidi, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert T. Smith, Susan Panozzo, Daisy Alapat, MD, Guido J. Tricot
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
We report @UAMSMyeloma the longest follow up of any myeloma phase III clinical trial @BloodAdvances @ASH_hematology #mmsm Long Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma ➡️ https://t.co/14jmt9SjjR Median OS: 13.3 yrs 🧵 https://t.co/Ml7lgdNbj3
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events Elena Zamagni, MD 1 *, Tobias Silzle, MD 2 *, Ivan Špička 3 *, Sabrin Tahri, MD 4 *, Sarah Lonergan 4 *, Inger S. Nijhof, MD, PhD 5 *, Antonietta Pia Falcone,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 1️⃣0️⃣ Majestec-4/EMN30 Trial ➡️ https://t.co/gAOFjnxR4S ✅Multiple cohorts comparing Tec alone, Tec-Len vs Len alone post ASCT- time limited maintenance in all pts Will be interesting to see if intensifying maintenance for 2 yrs will improve efficacy/safety https://t.co/KclSGJQAU1
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Study Population, Human Meletios-Athanasios Dimopoulos 1, Peter M. Voorhees, MD 2, Fredrik Schjesvold, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 3️⃣ AQUILA study ➡️ https://t.co/cBxHkGczl9 ✅ Dara vs active monitoring in smoldering myeloma ✅ n=390, median F/U: 5.5 yrs ✅ORR in 2/3 of pts 🛑one third of Dara pts received second line ttt Data on progression events will be imp https://t.co/jlYZOAaqNv
-
Thank you @ASCO daily news for covering what we will discuss along with my colleagues: @JayaniReena and @suvannasankha Harnessing the Immune System to Its Full Potential: Immunologic Approaches to Multiple Myeloma Management @UAMSMyeloma https://t.co/onbBFoYX73 Looking for